GOSSAMER BIO, INC. Operating Lease Liability
GOSSAMER BIO, INC. (GOSS) had Operating Lease Liability of $3.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability $3.92M.
- 2026-03-31: Operating Lease, Liability $4.17M.
- 2025-12-31: Operating Lease, Liability $4.40M.
- 2025-09-30: Operating Lease, Liability $4.62M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $3.92M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $4.17M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $4.40M 10-K · filed 2026-03-17 |
| 2025-09-30 | $4.62M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.82M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $5.02M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $5.36M 10-K · filed 2025-03-13 |
| 2024-09-30 | $6.34M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.83M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $2.65M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.45M 10-K · filed 2024-03-05 |
| 2023-09-30 | $4.21M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.97M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $5.71M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $6.43M 10-K · filed 2023-03-17 |
| 2022-09-30 | $7.12M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $7.80M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $8.47M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $6.12M 10-K · filed 2022-03-03 |
| 2021-09-30 | $6.99M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $9.57M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $10.47M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $11.35M 10-K · filed 2021-02-26 |
| 2020-09-30 | $12.20M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $11.10M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $10.52M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $11.09M 10-K · filed 2020-03-24 |
| 2019-09-30 | $11.63M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $12.17M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $12.71M 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |